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and normoxia, and neutralizing MIF-antibodies diminished TNF-฀ and IL-1฀ release in hypoxic ASCs.
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Background: Adipose-derived stem cells (ASCs) are multipotent mesenchymal stem
cells characterized by their strong regenerative potential and low oxygen consumption.
Macrophage migration inhibitory factor (MIF) is a multifunctional chemokine-like cytokine
that is involved in tissue hypoxia. MIF is not only a major immunomodulator but also is
highly expressed in adipose tissue such as subcutaneous adipose tissue of chronic non-
healing wounds. In the present study, we investigated the effect of hypoxia on MIF in
ASCs isolated from healthy versus inflamed adipose tissue.
Methods: Human ASCs were harvested from 17 patients (11 healthy adipose tissue
samples, six specimens from chronic non-healing wounds). ASCs were treated in a
hypoxia chamber at <1% oxygen. ASC viability, MIF secretion as well as expression
levels of MIF, its receptor CD74, hypoxia-inducible transcription factor-1α (HIF-1α)
and activation of the AKT and ERK signaling pathways were analyzed. The effect of
recombinant MIF on the viability of ASCs was determined. Finally, the effect of MIF
on the viability and production capacity of ASCs to produce the inflammatory cytokines
tumor necrosis factor (TNF), interleukin (IL)-6, and IL-1β was determined upon treatment
with recombinant MIF and/or a blocking MIF antibody.
Results: Hypoxic treatment inhibited proliferation of ASCs derived from healthy
or chronic non-healing wounds. ASCs from healthy adipose tissue samples were
characterized by a low degree of MIF secretion during hypoxic challenge. In contrast,
in ASCs from adipose tissue samples of chronic non-healing wounds, secretion and
expression of MIF and CD74 expression were significantly elevated under hypoxia. This
was accompanied by enhanced ERK signaling, while AKT signaling was not altered.
Recombinant MIF did stimulate HIF-1α expression under hypoxia as well as AKT and
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ERK phosphorylation, while no effect on ASC viability was observed. Recombinant MIF
significantly reduced the secretion of IL-1β under hypoxia and normoxia, and neutralizing
MIF-antibodies diminished TNF-α and IL-1β release in hypoxic ASCs.
Conclusions: Collectively, MIF did not affect the viability of ASCs from neither healthy
donor site nor chronic wounds. Our results, however, suggest that MIF has an impact
on the wound environment by modulating inflammatory factors such as IL-1β.
Keywords: adipose-derived stem cells, macrophage migration inhibitory factor, hypoxia, cytokine, chronic
wounds
INTRODUCTION
Besides their substantial burden to patients and treating
specialists, critical wounds also challenge global healthcare
systems financially. Critical wounds are classically treated by
wound dressing regimens and surgical debridements, but these
measures are only partially successful. Therefore, alternative
solutions are urgently needed. Regenerative medicine offers
innovative approaches in this regard as it capitalizes on body-
own resources to restore tissue damage. Promising developments
in the field are based on the use of adipose tissue due to its easy
harvest, high yields of mesenchymal stromal cells (MSCs) and
its hitherto largely underestimated reparative capacity. In fact,
potential regenerative medicine strategies are directed toward
the regulatory function of adipose tissue and its inherent cells
in body physiology. In regenerative medicine, adipose-derived
stromal cells (ASCs) are of particular interest and have been
studied extensively in the last two decades. ASCs are adult MSCs
with rich proliferation and differentiation potential and naturally
low oxygen consumption (Zuk et al., 2001). They are regarded
beneficial for a multitude of regenerative therapeutic approaches
such as ASC transplantation or ASC-enriched fat grafting into
chronic wounds. One major characteristic of chronic wounds
is a state of tissue hypoxia due to reduced tissue perfusion
(Pierpont et al., 2014). Inadequate oxygenation of tissue, a
phenomenon also seen in physiological conditions including
strenuous exercise and high altitudes or pathologies such as
obesity, cancer and ischemic diseases, stresses cells and in the
long run impairs cellular function (Ruthenborg et al., 2014).
However, the impact of hypoxia on MSC and ASC viability
and function is still controversial. Wang et al. (2005) found no
difference in the proliferation of primary human ASCs exposed
to 5 or 20% oxygen tension. Fehrer et al. (2007) and Estrada et al.
(2012), however, provided strong evidence that lower oxygen
tension increases growth and the lifespan of ASCs and bone
marrow-derived MSCs (BMSCs), respectively. These studies
were seconded by Choi et al. (2014) who observed increase
proliferation of primary ASCs and a specific enhancement in
chondrogenic differentiation. On the contrary, Holzwarth et al.
(2010) reported a decrease in the proliferation and osteogenic
differentiation of BMSCs under hypoxia.
Besides the proliferating and migratory capacity of ASCs,
the release of soluble factors from ASCs has been recognized
as the key mechanism to exert their regenerative potential
(Salgado et al., 2010). Hypoxic tension in ASCs has been shown
to even enhance their therapeutic function by positively
regulating their secretome (Chung et al., 2009; Choi et al., 2017).
A factor that may play a distinct role in ASC function
under hypoxic conditions is themacrophagemigration inhibitory
factor (MIF). MIF was one of the first cytokines to be
discovered over half a century ago. It was initially described as
a T lymphocyte-derived factor in the context of delayed-type
hypersensitivity reactions (David, 1966; Calandra and Roger,
2003). Today, MIF is known as a multifunctional chemokine-
like inflammatory cytokine that plays a key role in various
acute and chronic inflammatory diseases, autoimmunity, and
cardiovascular conditions including atherosclerosis (Bernhagen
et al., 1993; Calandra and Roger, 2003; Morand et al., 2006;
Zernecke et al., 2008; Müller et al., 2012; Tilstam et al., 2017; Kang
and Bucala, 2019). The physiological and pathogenic functions
of MIF as well as those of the MIF homolog D-dopachrome
tautomerase (D-DT/MIF-2) are mediated in a context- and cell-
dependent manner via interactions with one or a combination
of its receptors, i.e., CD74, CXCR2, CXCR4, or CXCR7 (Leng
et al., 2003; Bernhagen et al., 2007; Zernecke et al., 2008; Tilstam
et al., 2017; Kapurniotu et al., 2019). MIF is not only expressed
in immune cells but also in certain parenchymal cells and various
tissues (Calandra and Roger, 2003).
Notably, MIF’s high expression in adipose tissue was
documented early on (Skurk et al., 2005; Kim et al., 2015a,b).
MIF is considered to be an atypical chemokine and cytokine
that differs from classical cytokines by several characteristics.
For example, in contrast to other cytokines, MIF does not
contain an N-terminal signal peptide and is rapidly released
from preformed intracellular pools upon activation via several
stimulants (Weber et al., 2008).
Of note, MIF has been implicated in tissue hypoxia and
its expression and secretion has been shown to be induced by
hypoxia in various cell types including endothelial cells and
cancer cells (Oda et al., 2008; Simons et al., 2011). Moreover,
we recently discovered an adipokine-like property of MIF. MIF
is up-regulated in human subcutaneous adipose tissue samples
harvested from the vicinity of chronic non-healing wounds when
compared to adipose tissue samples from healthy donor sites
(Kim et al., 2015b). Importantly, MIF secreted by inflamed
adipose tissue samples impaired fibroblast proliferation in an
in vitro wound healing assay (Kim et al., 2015b).
In the present study, we investigated the effect of hypoxia
on human ASCs from healthy donor sites and the vicinity of
chronic non-healing wounds.We analyzed the expression ofMIF,
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its receptor CD74 as well as AKT and ERK phosphorylation,
two common MIF signaling pathways mediating survival and
apoptosis, in response to hypoxic challenge (Lue et al., 2006,
2007). Furthermore, we added recombinant MIF to normoxic
and hypoxic ASCs and assessed their proliferation as well as
cytokine production capacity to further evaluate a potential
therapeutic value of MIF. Due to MIF’s role as an upstream
regulator of multiple cytokines (Calandra and Roger, 2003),
we also investigated the secretion profile of interleukin (IL)-
6, IL-1β, and tumor necrosis factor (TNF)-α that have been
shown to affect wound repair (Kondo and Ohshima, 1996). We
hypothesized that MIF secretion is increased under hypoxia as
found within the majority of chronic non-healing wounds. We
also hypothesized that ASCs isolated from adipose tissue from
healthy and chronic non-healing wound donor sites may react
differently upon hypoxia, may have a significant impact on the





Adipose-derived stem cells (ASCs) were isolated from human
adipose tissue obtained from elective surgeries of the Department
of Plastic and Reconstructive Surgery, Hand Surgery–Burn
Center of the RWTH University Hospital Aachen according
to a modified protocol by Zuk et al. (2001) and Pallua
et al. (2009). In short, subcutaneous adipose tissue that was
en bloc excised during surgery was immediately transferred
to the laboratory. The adipose tissue samples were washed
with phosphate buffered saline (PBS). Blood vessels, connective
tissue and dead tissue were removed. Next, the adipose tissue
samples was minced and incubated with 0.2% collagenase (type
I; Worthington Biochemical, Lakewood, NJ, United States)
under constant shaking for 37◦D for 45 min. The collagenase
digestion was stopped by Dulbecco’s modified eagle medium
(DMEM)/F12 (Invitrogen, Karlsruhe, Germany) containing 10%
fetal calf serum (FCS) (Gibco, Eggenstein, Germany). The
digested fat was filtered through a 100 µm mesh, centrifuged
at 132 × g for 5 min. The resulting pellet represents the
stromal vascular fraction (SVF). The SVF was resuspended in a
medium containing DMEM/F12 supplemented with 10% FCS,
1 ng/ml basic fibroblast growth factor (bFGF) (R&D Systems,
Minneapolis, MN, United States) and 1% penicillin/streptomycin
(Gibco, Eggenstein, Germany) in a humidified incubator at 37◦C
and 5% CO2 to differentiate to ASCs.
Characterization of ASCs was done according to the
recognized criteria of the International Society for Cellular
Therapy (ISCT) and for Adipose Therapeutics and Science
(IFATS) which include plastic adherence in culture, trilinear
differentiation (adipogenic, osteogenic, and chondrogenic)
and marker expression (Dominici et al., 2006; Bourin et al.,
2013). Upon incubation with respective differentiation media,
adipogenic differentiation was confirmed by oil red O staining
(Sigma-Aldrich Corporation, St Louis, MO, United States),
chondrogenic differentiation by Alcian-PAS blue (Merck
Millipore, Burlington, VT, United States) and osteogenic
differentiation by Alizarin red staining (Sigma-Aldrich
Corporation, St Louis, MO, United States) according to well-
established protocols (Yoshinoya et al., 2020). By flow cytometry,
following surfacemarkers were determined on a LSR II cytometer
(BD Bioscience, San Jose, CA, United States) according to earlier
protocols (Pallua et al., 2018): CD31-eFluor450, CD34-FITC,
CD45-PerCP-Cy5.5, CD73-PE-Cy7, CD90-PE, and CD105-APC.
ASCs were negative for the hematopoietic marker CD45- and
the endothelial marker CD31- but positive for the MSC markers
CD34, CD73, CD90, and CD105 (Bourin et al., 2013; Yoshinoya
et al., 2020).
Adipose-derived stem cells from 17 fat tissue donors (see
Tables 1, 2 for closer characteristics) were included in the hypoxic
versus normoxic experiment and categorized into two groups.
Fat tissue donors in group A (11 donors, five male, six female,
46.82 ± 14.57 years, mean BMI 28.31 ± 3.93 kg/m2 underwent
elective procedures. Adipose tissue samples in group B (six
donors, three male, three female, mean age 47.83 ± 11.91 years,
mean BMI 30.45± 4.43 kg/m2) were obtained from chronic non-
healing wounds which underwent surgical wound debridement.
Only viable adipose tissue from non-healing wounds was used
whereas necrotic and infected parts were used for clinical
sampling or discarded. Informed consent was obtained from
all patients, and ethical approval was provided by the ethics
committee of RWTH Aachen University (EK 213/17) and the
cantonal ethics committee Zurich (BASEC-Nr 2019-00389).
Experiments were conducted in accordance with the Declaration
of Helsinki Principles.
Hypoxic Treatment of ASCs
A commercially available hypoxia chamber (Coy Laboratory
Products, Grass Lake, MI, United States) was continuously
flooded with 95% nitrogen (N2) and 5% CO2 to maintain a
hypoxic environment below 1% O2. Deoxygenation of growth
and starvation media supplemented with 10 and 1% FCS,
respectively, was achieved as previously described (Simons et al.,
2011). ASCs at passage three were seeded at a density of
10,000 cells/cm2 in growth medium. All cells were incubated at
37◦C and 5% CO2 overnight to facilitate cell adherence before
hypoxic or normoxic treatment.
Detection of Cell Viability Under
Normoxia and Hypoxia
The viability of ASCs was documented by microscopic
photographs and quantified using Trypan Blue staining
(Invitrogen, Karlsruhe, Germany) and a TC20 Automated
Cell Counter (Bio-Rad, Munich, Germany) according to the
manufacturer’s guidelines. The metabolic activity of ASCs
was quantified using PrestoBlue (Invitrogen, Karlsruhe,
Germany) according to the manufacturer’s manual. Fluorescence
was measured at 560 nm excitation and 590 nm emission
with wavelength correction by a Wallac Victor 1420
multilabel counter.
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TABLE 1 | Details of healthy adipose tissue samples in group A.
Number Age Sex BMI Location Applied Assays
1 38 Male 29.07 Lower leg MIF ELISA
2 56 Male 26.12 Abdomen Proliferation, MIF ELISA
3 31 Male 24.38 Breast Proliferation, MIF ELISA
4 37 Male 25.25 Abdomen Proliferation, MIF ELISA, MIF Dose: Proliferation and Western Blot
5 65 Female 36.33 Abdomen MIF Dose: Proliferation and Western Blot
6 36 Female 29.3 Upper thigh MIF stimulation, ELISA (IL-6, IL-1β, TNF-α), Western Blot (CD74, HIF-1α)
7 76 Male 28.9 Abdomen MIF stimulation, ELISA (IL-6, IL-1β, TNF-α), Western Blot (CD74, HIF-1α)
8 45 Female 22.2 Abdomen MIF stimulation, ELISA (IL-6, IL-1β, TNF-α), Western Blot (CD74, HIF-1α)
9 30 Female 32.7 Abdomen MIF stimulation, ELISA (IL-6, IL-1β, TNF-α), Western Blot (CD74, HIF-1α)
10 51 Female 27.5 Abdomen MIF stimulation, ELISA (IL-6, IL-1β, TNF-α),
11 50 Female 29.7 Upper thigh MIF stimulation, ELISA (IL-6, IL-1β, TNF-α),
TABLE 2 | Details of adipose tissue samples from chronic non-healing wounds in group B.
Number Age Sex BMI Location Applied Assays
12 27 Male 25.9 Upper leg Proliferation, MIF ELISA, Western Blot
13 51 Female 27.82 Abdomen Proliferation, MIF ELISA, Western Blot
14 56 Female 35.75 Upper leg Proliferation, MIF ELISA, Western Blot, MIF Dose: Proliferation and Western Blot
15 41 Female 29.5 Abdomen MIF neutralization, ELISA (IL-6, IL-1β, TNF-α), Western Blot (CD74, HIF-1α)
16 59 Male 27.5 Upper leg MIF neutralization, ELISA (IL-6, IL-1β, TNF-α), Western Blot (CD74, HIF-1α)
17 53 Male 36.2 Upper leg MIF neutralization, ELISA (IL-6, IL-1β, TNF-α), Western Blot (CD74, HIF-1α)
Quantification of Cytokine Secretion by
Enzyme-Linked Immunosorbent Assay
(ELISA)
Levels of MIF, IL-6, IL-1β, and TNF-α in the supernatants
of ASCs were measured by enzyme-linked immunosorbent
assay (ELISA) (human MIF, human IL-6, human IL-1
beta/IL-1F2 and human TNF-alpha Duo Set ELISA kit,
R&D Systems, Minneapolis, MN, United States) according to
the manufacturer’s manual. Color intensity was measured using
a Wallac Victor 1420 multilabel counter or EnSpire Multimode
Plate Reader (PerkinElmer, Rodgau, Germany) set at 450 nm
with wavelength correction.
Analysis of the Expression of MIF, CD74,
HIF-1α, and AKT and ERK Signaling
Using Western Blot
The expression levels of hypoxia-inducible transcription factor-
1α (HIF-1α), intracellular MIF, its receptor CD74, as well as the
phosphorylation levels of AKT and ERK, and finally, tubulin for
total protein standardization was performed by Western blot as
previously described (Lue et al., 2006).
Cell lysates of ASCs at indicated measurement points (see
section “Results”) were acquired using 1× LDS/DTT buffer
[25% (v/v) NuPAGE lithium dodecyl sulfate (LDS) sample buffer
(Invitrogen, Karlsruhe, Germany), 50 mM dithiothreitol (DTT)
(Sigma-Aldrich, Munich, Germany), bidistilled water (ddH2O)].
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) for MIF (12.5 kDa) and CD74 (40 kDa) or HIF-
1α (120 kDa), AKT (60 kDa), and ERK-1/2 (42–44 kDa)
analysis using 15 or 10% polyacrylamide gels, respectively, and
Western blotting was performed according to standard protocols
(Lue et al., 2006). The following primary antibodies were
used: rabbit anti-HIF-1α (D1S7W; Cell Signaling Technology,
Beverly, MA, United States), goat anti-CD74 (C-16 or LN-
2) (Santa Cruz Biotechnology, Heidelberg, Germany), mouse
anti-αTubulin (B512; Sigma-Aldrich, Munich, Germany or B-
7, Santa Cruz Biotechnology, Heidelberg, Germany), mouse
anti-ERK1/2 (C-9) and anti-pERK-1/2 (12D4; Santa Cruz
Biotechnology, Heidelberg, Germany), rabbit anti-AKT (11E7)
and anti-pAKT (Ser473; Cell Signaling Technology, Beverly,
MA, United States). The polyclonal rabbit anti-MIF antibody
(Ka565) was previously described (Schober et al., 2004). Mouse
anti-rabbit Peroxidase IgG (Jackson ImmunoResearch, Ely,
United Kingdom), rabbit anti-goat-HRP (Pierce Biotechnology,
Rockford, IL, United States), donkey anti-mouse-HRP (Abcam,
Cambridge, MA, United States), goat anti-mouse-HRP (Abcam,
Cambridge, MA, United States) and donkey anti-rabbit-HRP
(GE Healthcare, Munich, Germany) were employed as secondary
antibodies. Blotted bands were detected using the LAS-3000
image reader (Fujifilm, Düsseldorf, Germany) and quantified
by AIDA image analyzer software (Raytest Isotopen GmbH,
Berlin, Germany) or Image J (1.53a, National Institutes of
Health, United States).
MIF Stimulation and Neutralization
Experiment
Briefly, 10,000 ASCs/cm2 were incubated in growth medium
overnight at 37◦C and 5% CO2. To study the effect of
recombinant MIF on the viability of ASCs, cells were subjected to
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hypoxic versus normoxic treatment in the presence of different
MIF concentrations (100, 250, and 500 ng/ml, as determined
in a prior dose response scouting experiment) that were added
at 0, 24, 48, and 72 h. The influence of exogenous MIF on
cytokine release and expression of HIF-1α and intracellular
CD74 were studied by using ASCs stimulated with 100 ng/ml
recombinant MIF at normoxic or hypoxic conditions for 24 h.
Biologically active, recombinant human MIF was prepared as
described previously (Bernhagen et al., 1994; Kleemann et al.,
2000). For neutralization experiments, 8000 nM of anti-MIF
monoclonal antibody NIH/IIID.9 was applied at normoxic or
hypoxic conditions for 24 h. The control group received PBS in
all experiments.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism version
8 (La Jolla, CA, United States). Samples were tested for normality
using Shapiro–Wilk test. For experiments comparing the effect
of normoxic and hypoxic condition either over time or following
stimulation with vehicle or recombinant MIF on the functional
biology of ASCs, two-way ANOVA was applied and corrected
for multiple comparisons using the Holm-Šídák method. The
effect of the MIF-dose response on the activation of stress kinases
was statistically evaluated using one-way ANOVA corrected by
Holm-Šídák’s multiple comparisons test. Unpaired, two-sided
t-tests were performed for MIF neutralization experiments in
hypoxic ASCs isolated from chronic non-healing wounds. Results
are presented as mean values with the standard error of the mean
(SEM). Asterisks indicate statistical significance, considered as a
p-value below 0.05.
RESULTS
ASCs Meet ISCT/IFATS Criteria
Adipose-derived stem cells were characterized according to ISCT
and IFATS criteria on MSCs. ASCs in cultured showed plastic
FIGURE 1 | Viability of ASCs under normoxic and hypoxic conditions. Cells were cultured in starvation or growth medium at normoxic oxygen levels of 21% O2 or
hypoxic oxygen levels of <1% O2. Viability of ASCs was measured by Trypan Blue staining and counting in relation to the baseline value at 4 h normoxia, set to one.
Graphs display pooled effects of ASCs isolated from patient Group A and B cultured in (A) starvation medium (n = 6) and (B) growth medium (n = 6). ASCs
harvested from (C) healthy donor sites (Group A, n = 3) and (D) chronic, non-healing wounds (Group B, n = 3) exert similar proliferation behavior when cultured in
growth medium. Data are represented as mean values ± SEM (two-way ANOVA, Holm-Šídák’s multiple comparisons test, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001,
∗∗∗∗p < 0.0001).
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adherence and differentiated into the osteogenic, chondrogenic
and adipogenic line (Supplementary Figure 1). Furthermore,
ASCs were negative for the markers CD31/CD45 but positive
for the stem cell markers CD34, CD73, CD90, and CD105
(Supplementary Figure 2).
Hypoxia Reduces the Proliferation of
ASCs
We firstly tested the effect of hypoxia on the viability of ASCs.
We examined the effect of hypoxia and different cell media
composition on cell survival using starvation medium to mimic
the state of nutrient deprivation in wounds, and growth medium
to exclude effects of nutrient deficiency. Cells from group A
(healthy donor sites) and group B (chronic non-healing wounds)
were both examined. ASC proliferation was inhibited at oxygen
levels below 1%, while the number of ASCs increased significantly
at 48 h and 72 h under normoxic conditions. Compared to
growth medium, nutrient deprivation seems to slow down the
proliferation rate of normoxic ASCs (Figures 1A,B). Thus,
proliferation of ASCs maintained in growth medium and under
normoxia were significantly increased at 48 and 72 h compared
to those kept under hypoxic conditions. The hypoxia-associated
restriction in cell proliferation was independent of patient group
(Figures 1C,D). Together, the experiment showed that hypoxic
treatment reduces cell proliferation.
Hypoxic Treatment Induces MIF
Secretion
We next wished to study whether the effect of hypoxia altered
MIF secretion. MIF secretion levels in the supernatants of ASCs
cultured under hypoxic conditions were compared to those
under normoxic conditions. As we did not differentiate between
patient group A and B, results of both specimens were pooled
in this part. Starvation medium was utilized to limit the possible
interference of FCS in the ELISA (Kragstrup et al., 2013). Figure 2
illustrates that MIF secretion was increased by the hypoxic
challenge at all time intervals studied. Maximum secretion was
observed 72 h after the start of hypoxia with an accumulated MIF
concentration of 300 pg/ml, corresponding to a two-fold increase
over MIF secretion under normoxic conditions (not significant).
The results indicate that MIF secretion may be elevated by
hypoxic challenge of ASCs.
Hypoxia-Induced MIF Secretion Is
Elevated in ASCs From Adipose Tissue
of Chronic Non-healing Wounds
Previous studies described the up-regulation of MIF expression
in human subcutaneous adipose tissue specimens from chronic
non-healing wounds when compared to healthy donor sites (Kim
et al., 2015b). We therefore compared hypoxia-stimulated MIF
secretion between ASCs isolated from healthy (group A) and
inflamed adipose tissue specimens (group B) next. ASCs from
healthy adipose tissue samples (group A) were characterized
by low MIF secretion levels under hypoxic conditions with
no statistical difference to the normoxic control (Figure 3A).
By contrast, hypoxia-induced MIF secretion in ASCs isolated
from group B individuals with chronic non-healing wounds
was markedly increased when compared to normoxic treatment
reaching statistical significance after 72 h (p < 0.05) (Figure 3B).
The results indicate that hypoxia-induced MIF secretion is
specifically increased in ASCs samples from adipose tissue
samples of chronic non-healing critical wounds whereas hypoxia
FIGURE 2 | Migration inhibitory factor (MIF) secretion levels under normoxic and hypoxic conditions. Cells were cultured in starvation medium at normoxic oxygen
levels of 21% O2 or hypoxic oxygen levels of <1% O2. Supernatants of ASCs were collected at indicated measuring points and ELISA was performed to determine
MIF secretion by ASCs under normoxic and hypoxic conditions. Baseline levels (BL) were obtained at the starting point 0 h. The graph displays pooled results from
patients group A (healthy donor sites) and group B (chronic non-healing wounds). Analyses were performed for seven biological replicates (n = 7). Data are mean
values ± SEM (two-way ANOVA, Holm-Šídák’s multiple comparisons test, not significant).
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FIGURE 3 | Migration inhibitory factor (MIF) secretion levels under normoxic and hypoxic conditions in patient groups A and B. Cells were cultured in starvation
medium at normoxic oxygen levels of 21% O2 or hypoxic oxygen levels of 1% <O2. Separate replicates were cultured for indicated culture periods for independent
measurements. Supernatants of ASCs were collected at indicated measuring points and ELISA was performed to determine MIF secretion by ASCs under normoxic
and hypoxic conditions. Baseline levels (BL) were obtained at the starting point 0 h. Fat donors were arranged in two groups and analyses were performed for four or
three biological replicates, respectively. Group A included healthy adipose tissue samples and group B adipose tissue samples from chronic non-healing wounds.
Results are displayed for (A) patient group A (n = 4) and (B) patient group B (n = 3). Data are mean values ± SEM (two-way ANOVA, Holm-Šídák’s multiple
comparisons test, ∗p < 0.05).
has no influence on the MIF secretion from ASCs derived from
healthy donor sites.
MIF Secretion and Expression Under
Hypoxia Correlates With CD74
Expression Levels in ASCs Isolated From
Adipose Tissue of Chronic Non-healing
Wounds
Based on the finding that MIF secretion was specifically
and strongly elevated in ASCs isolated from chronic non-
healing adipose tissue, ASCs from patient group B were
further scrutinized. Western blot analysis was used to confirm
the effect of hypoxia on MIF secretion and to examine
expression of CD74. Enhanced MIF secretion was accompanied
by significantly elevated cellular MIF expression levels under
hypoxic culture of ASCs from chronic non-healing wounds when
compared to normoxic conditions (Figure 4). This difference
was statistically significant at 72 h after starting the hypoxic
challenge (p < 0.0001). The hypoxia-triggered up-regulation of
MIF at later time points was mirrored by the CD74 expression
profile, reaching statistical significance at 72 h hypoxia (p< 0.01).
The results demonstrate a potential correlation between hypoxia-
induced MIF secretion and CD74 expression in ASCs isolated
from chronic non-healing adipose tissue of patient group B.
Elevated MIF Secretion After Hypoxic
Challenge Is Accompanied by Altered
ERK Signaling in ASCs Isolated From
Adipose Tissue of Chronic Non-healing
Wounds
The relationship between hypoxia-induced MIF secretion and
cell signaling was further examined in ASCs from patient
group B. We chose to analyze the PI3K/AKT and MAPK/ERK
signaling pathways as they are prominently involved in cell
survival and have been associated with MIF and its receptors
(Zernecke et al., 2008). AKT phosphorylation did not change
significantly under hypoxia, neither over the time course nor
when compared to normoxic conditions, although a trend
toward increased hypoxia-induced AKT phosphorylation was
seen at 72 h (Figures 5A,B). ERK activation gradually attenuated
over the time course, both under hypoxic and normoxic
conditions. Overall, pERK/ERK ratios were increased at 4, 48,
and 72 h of hypoxic challenge under hypoxia as compared to
normoxia with a significant increase at 4 h hypoxia (p < 0.05)
(Figures 5A,C). The results suggest a link between the hypoxia-
induced increase in MIF secretion and the altered CD74/ERK
signaling response in ASCs.
Treatment With Exogenous Recombinant
MIF May Dose-Dependently Activate
AKT and ERK Signaling in ASCs, but
Does Not Alter ASC Viability Under
Hypoxia
To directly test the effects of MIF stimulation, we incubated
ASCs with recombinant MIF. MIF dose-dependently enhanced
the levels of phosphorylated ERK and AKT, with a maximal effect
of two-fold up-regulation seen at 250 ng/ml MIF, but the MIF
dose effect did not reach statistical significance (not significant;
Figure 6). This observed trend is in line with previous reports in
other cell types (Lue et al., 2007; Zhang et al., 2012).
We next recorded the viability of ASCs under hypoxic and
normoxic conditions and tested the effect of recombinant MIF.
Since AKT and ERK are well-known mediators of proliferation,
we next tested the effect of recombinant MIF on the viability
of ASCs under hypoxic and normoxic conditions. While the
viability of ASCs increased in a time-dependent manner with
a maximum observed after 48 h, no effect of hypoxia or MIF
treatment was noted (Figure 7). In summary, recombinant
MIF did not have any effects on cell viability, although it
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FIGURE 4 | Expression levels of MIF and CD74 under normoxia and hypoxia in patient group B. Group B included three adipose tissue specimens from chronic
non-healing wounds, which exhibited high MIF secretion in the hypoxic culture of ASCs. Cells were cultured in growth medium at normoxic oxygen levels of 21% O2
or hypoxic oxygen levels of <1% O2. Cell lysates were obtained at indicated measuring points. Western blot analysis was performed and evaluated using the AIDA
software. Tubulin was detected for total protein standardization. (A) Blots are representative of all Western blots performed to detect levels of MIF, CD74, and tubulin.
Analyses were performed for three biological replicates, respectively (n = 3). The graphs display (B) relative MIF/tubulin and (C) relative CD74/tubulin normalized to
the baseline value (BL) at 0 h, set to one. Data are mean values ± SEM (two-way ANOVA, Holm-Šídák’s multiple comparisons test, ∗∗p < 0.01, ∗∗∗∗p < 0.0001).
FIGURE 5 | AKT and ERK phosphorylation in ASCs under normoxia and hypoxia in patient group B. Group B included adipose tissue samples from chronic
non-healing wounds, which exhibited high MIF secretion in the hypoxic culture of ASCs. Cells were cultured in growth medium at normoxic oxygen levels of 21% O2
or hypoxic oxygen levels of <1% O2. Cell lysates were obtained at indicated measuring points and Western blot analysis was performed and evaluated using the
AIDA software. Tubulin was detected for total protein standardization. (A) Blots are representative of all Western blots performed to detect levels of phosphorylated
AKT (pAKT), AKT, phosphorylated ERK (pERK), and ERK. Analyses were performed for three biological replicates (n = 3). The graphs display (B) relative pAKT/AKT
and (C) relative pERK/ERK were normalized to the baseline value at 0 h, set to one. Data are mean values ± SEM (two-way ANOVA, Holm-Šídák’s multiple
comparisons test, ∗p < 0.05).
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FIGURE 6 | AKT and ERK phosphorylation after MIF stimulation. ASCs were cultured in growth medium at normoxic oxygen levels of 21% O2 for 24 h and then
stimulated with various concentrations of exogenous MIF for 15 min. The control (0 ng/ml) did not receive any exogenous MIF. Cell lysates were obtained and
Western blot analysis was performed and evaluated using the AIDA software. Tubulin was detected for total protein standardization. (A) Blots are representative of all
Western blots performed to detect levels of AKT and ERK activation. Analyses were performed on five biological replicates (n = 5). Graphs display (B) relative
pAKT/AKT and (C) relative pERK/ERK normalized to the activation level of unstimulated cells set to one. Data are mean values ± SEM (one-way ANOVA,
Holm-Šídák’s multiple comparisons test, not significant).
appears to lead to AKT and ERK phosphorylation in a dose-
dependent manner.
Recombinant MIF and Hypoxia
Synergistically Enhance HIF-1α Protein
Expression in ASCs
It was shown earlier that HIF-1α induces MIF expression
(Welford et al., 2006; Simons et al., 2011), while MIF
amplifies HIF-1α stabilization, prompting a positive feedback
that leads to further MIF expression (Winner et al., 2007).
In a hypoxic environment, MIF mediates HIF-1α expression
by stimulation of its cognate receptor CD74 and activation
of the ERK/mammalian target of rapamycin (mTOR) pathway
(Gaber et al., 2011). To study a possible link between
secreted, exogenous MIF, CD74, and HIF-1α expression and
the proliferation of ASCs, we assessed HIF-1α and CD74
levels in normoxic and hypoxic ASCs treated with recombinant
MIF (Figure 8). There was a trend toward increased levels
of CD74 under hypoxic conditions, while CD74 expression
was unaffected by recombinant MIF (Figure 8B). HIF-1α is
not stabilized in normoxic ASCs whereas low volumes were
detectable under hypoxia. Of note, recombinant MIF also led
to a substantial significant up-regulation of HIF-1α (>10-fold)
compared to vehicle-treated control cells (p < 0.01) (Figure 8C).
The data suggest that exogenous MIF stabilizes HIF-1α, an
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FIGURE 7 | Viability of ASCs under normoxic and hypoxic conditions after MIF stimulation. Cells were stimulated with 100, 250, or 500 ng/ml of recombinant MIF
and cultured in growth medium at normoxic oxygen levels of 21% O2 or hypoxic oxygen levels of <1% O2. Treatment with exogenously added MIF was repeated
every 24 h of culture. Viability of ASCs measured by Presto Blue assay was calculated in relation to the baseline value (BL) of the control (0 ng/ml) that did not receive
any exogenous MIF at 4 h normoxia, set to one. Analyses were performed on three biological replicates (n = 3). Results are displayed for ASCs cultured in (A)
normoxia and (B) hypoxia. Data are mean values ± SEM (two-way ANOVA, Holm-Šídák’s multiple comparisons test, not significant).
effect that might mechanistically be facilitated by CD74 under
hypoxic conditions.
Recombinant MIF Reduces IL-1β
Secretion From ASCs
Soluble factors released from ASCs have been recognized as
a major mode of action of ASCs (Salgado et al., 2010). The
secretome of ASCs can be profoundly boosted by conditioning
ASCs with hypoxic or inflammatory stimulus.
Because MIF has an established role as an upstream regulator
of multiple cytokines (Calandra and Roger, 2003) and is rapidly
released following hypoxia, we hypothesized that MIF may
influence the release of other soluble factors and thereby
modulate the paracrine capacity of ASCs. Following stimulation
with recombinant MIF under normoxic and hypoxic conditions,
we measured the secretion of IL-6, TNF-α, and IL-1β, all
of which have been shown to be secreted by MSCs (Paquet
et al., 2015; Antebi et al., 2018) and to be downstream targets
of MIF (Calandra and Roger, 2003). Under the conditions
used in our experimental set-up, neither recombinant MIF nor
hypoxia showed an effect on IL-6 or TNF secretion of ASCs,
although there was a trend toward higher released IL-6 levels in
incubations with hypoxic versus normoxic ASCs, (Figures 9A,B).
Interestingly, the secretion of IL-1β was significantly decreased
by recombinant MIF treatment, both under normoxic and
hypoxic conditions, while hypoxia itself had no significant
effect (Figure 9C).
Paracrine/Autocrine MIF Activity Is
Involved in TNF-α Release From ASCs
Under Hypoxic Conditions
To further study the role of MIF in the release of the cytokines
IL-6, TNF-α, and IL-1β in ASCs following hypoxia and to
better understand its paracrine or autocrine activity, ASCs
obtained from chronic non-healing wounds were treated with a
blocking MIF antibody and cultured under hypoxic conditions.
Supernatants of ASCs were collected 24 h after induction of
hypoxia, and ELISAs performed to assess cytokine secretion.
While IL-6 levels remained unaffected following
neutralization of paracrine MIF in hypoxic ASCs from chronic
non-healing adipose tissue (Figure 10A), TNF-α levels were
strongly reduced (p < 0.05) (Figure 10B). IL-1β levels were
also reduced, but this effect did not reach statistical significance
(p < 0.11) (Figure 10C). Comparable levels of IL-6 and TNF-α
released from ASCs from healthy and inflamed donor sites
following hypoxia (Figures 9A,B versus Figures 10A,B) confirm
that IL-6 and TNF-α secretion remains unaffected by higher
concentrations of exogenous MIF. Furthermore, secreted levels
of IL-1β are comparable between hypoxic ASCs isolated from
adipose tissue of chronic non-healing wounds and hypoxic ASCs
from healthy donor sites stimulated with recombinant MIF,
which constitutes the experimental equivalent to wound ASCs,
while the control group (hypoxia + PBS) seem to secrete higher
amounts of IL-1β. In aggregate, these findings may suggest
that IL-1β secretion is down-regulated in ASCs from chronic
non-healing wounds (Figure 9C versus Figure 10C).
DISCUSSION
Tissue hypoxia is a condition of insufficient oxygen supply that
is found in several conditions including critical wounds. Adipose
tissue from subcutaneous layers adjacent to chronic non-healings
wounds may experience prolonged hypoxia due to reduction
in blood perfusion and other factors (Sen, 2009). Key cells in
the context of adipose tissue and wound hypoxia are ASCs,
stem cells of mesenchymal origin with considerable reparative
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FIGURE 8 | HIF-1α and CD74 expression after MIF stimulation in normoxic and hypoxic ASCs. ASCs from healthy donor sites (Group A) were stimulated with
100 ng/ml of recombinant MIF and cultured in growth medium at normoxic oxygen levels of 21% O2 or hypoxic oxygen levels of <1% O2. Control cells (0 ng/ml)
received PBS as vehicle. Cells were lysed 24 h after induction of hypoxia and Western blot analysis was performed and evaluated using Image J software. Tubulin
was detected for total protein standardization. (A) Representative blots of HIF-1α and CD74 expression in normoxic and hypoxic ASCs are depicted. Analyses were
performed on four biological replicates (n = 4). Band intensities were quantified and graphically displayed as (B) relative CD74/tubulin and (C) relative HIF-1α /tubulin
and normalized to the respective control group (PBS + normoxia). Data are mean values ± SEM (two-way ANOVA, Holm-Šídák’s multiple comparisons test,
∗∗p < 0.01).
functions. The pleiotropic adipokine and cytokine MIF has been
identified in different entities of adipose tissue inflammation
including obesity and wound healing, which share a state of tissue
hypoxia (Semenza, 2003; Brahimi-Horn and Pouyssegur, 2007).
Moreover, MIF was shown to be up-regulated under hypoxia
in endothelial and cancer cell lines (Oda et al., 2008; Simons
et al., 2011). This study served to elucidate the effects of hypoxia
and MIF on human ASCs derived from healthy donor sites and
chronic non-healing wounds. We found that hypoxia did not
induce proliferation/viability of ASCs but led to an increased
MIF expression and secretion as well as CD74 expression over
time. Interestingly, a distinct increase in MIF secretion was
observed in ASCs harvested from chronic non-healing wounds
when compared to ASCs from healthy donor sites. Elevated MIF
secretion under hypoxia was paralleled by altered ERK signaling,
at an early hypoxia induction time point of 4 h. Yet, recombinant
MIF did not have any effect on ASC viability under hypoxia,
although it contributed to the up-regulation of stabilization
and/or expression of HIF-1α. The addition of exogenous MIF
significantly reduced IL-1β secretion from ASCs, while IL-6 and
TNF-α remained unaffected.
In regenerative medicine, ASCs attract great interest as
a cell source for clinical applications owing to their high
reparative capacity. More than that, the in vivo stem cell niche is
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FIGURE 9 | Release of IL-6, TNF-α, and IL-1β from ASCs from healthy donor site (Group A) following hypoxia and stimulation with recombinant human MIF. Cells
were stimulated with 100 ng/ml of recombinant MIF and cultured in growth medium at normoxic oxygen levels of 21% O2 or hypoxic oxygen levels of <1% O2.
Supernatants of ASCs were collected at 24 h after induction of hypoxia and ELISA was performed to assess cytokine secretion by ASCs under normoxic and
hypoxic conditions. Results are displayed for (A) IL-6 (n = 6), (B) TNF-α (n = 6), and (C) IL-1β (n = 6). Data are mean values ± SEM (two-way ANOVA, Holm-Šídák’s
multiple comparisons test, ∗∗p < 0.01).
FIGURE 10 | Release of IL-6, TNF-α, and IL-1β from ASCs from chronic non-healing wounds (Group B) following hypoxia and neutralization of exogenous MIF via an
anti-MIF antibody. Cells were treated with anti-MIF antibody (NIH/IIID.9) and cultured in growth medium at hypoxic oxygen levels of <1% O2. Supernatants of ASCs
were collected at 24 h after induction of hypoxia and ELISA were performed to assess cytokine secretion by ASCs under normoxic and hypoxic conditions. Results
are displayed for (A) IL-6 (n = 3), (B) TNF-α (n = 3), and (C) IL-1β (n = 3). Data are mean values ± SEM (unpaired, two-sided t-test, not significant). ∗p < 0.05.
characterized by oxygen levels below 2% in humans (Mohyeldin
et al., 2010), whereas non-physiologically high oxygen levels
generate exogenous oxidative stress and cell senescence (Estrada
et al., 2012). Consequently, the question arises how tissue
hypoxia influences properties of ASCs and if exogenous factors
such as MIF may have a beneficial effect. We first sought to
investigate the effect of hypoxic culture conditions on ASC
viability when compared to normoxia. While previous studies
reported controversial effects of hypoxia on the viability of
various cell types including MSCs (Wang et al., 2005; Estrada
et al., 2012; Yamamoto et al., 2013; Choi et al., 2014), the
present study demonstrated that hypoxic treatment at <1% O2
for 72 h does not enhance ASC proliferation. The proliferation
behavior of ASCs isolated from healthy adipose tissue and
chronic non-healing wounds was similar under normoxia and
hypoxia. As a limitation, our measurements were restricted to
72 h and therefore evaluation of a potential effect of hypoxic
conditions beyond that time frame was not possible. It was
shown that ASCs under hypoxic culture for one or 2 weeks
exert pro-proliferative effects of hypoxia (Wang et al., 2005;
Estrada et al., 2012; Yamamoto et al., 2013; Choi et al., 2014).
Decreased proliferation of human MSCs in hypoxic culture was
linked to a resting state, indicating decelerated cell division and
differentiation (Holzwarth et al., 2010).
We found significantly elevated MIF secretion and expression
after hypoxic challenge in ASCs isolated from non-healing
chronic wounds, whereas ASCs from healthy donor sites did
not increase MIF secretion upon hypoxia. These results support
our previous finding that MIF expression is associated with
hypoxia, and that MIF is over-expressed in non-healing wounds
(Calandra and Roger, 2003; Wang et al., 2007; Kim et al., 2015b).
Furthermore, our observations indicate that hypoxia triggers
MIF-expression/secretion more easily in cells that already were
exposed to an inflammatory status in the past. The underlying
mechanisms are subject to further investigations.
Next, the expression of CD74 as one of the receptors involved
in MIF-driven pathways of inflammation as well as proliferation
and protection was examined (Leng et al., 2003). An elevation
of MIF secretion by ASCs from chronic non-healing wounds
upon hypoxia was accompanied by an up-regulated MIF and
CD74 expression. To gain an insight into MIF-CD74-dependent
signaling, we analyzed PI3K/AKT andMAPK/ERK pathways that
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are involved in cell survival and apoptosis in response to hypoxia
(Leng et al., 2003; Lue et al., 2006, 2007). Skin injury models
have suggested that the cutaneous healing capacity of hypoxia-
conditioned MSCs may be mediated via PI3K/AKT pathways
(Jun et al., 2014). MIF-dependent AKT signaling protects against
reperfusion injury in the ischemic heart (Zernecke et al., 2008;
Pohl et al., 2016), whilst it delays cellular senescence and
enhances multipotency of MSCs (Palumbo et al., 2014; Xia et al.,
2015). Interestingly, ERK phosphorylation was increased under
hypoxia, while no significant changes of AKT signaling were
observed. Missing effects on AKT activation in our experiments
may be explained by our limitedmeasurement time points that do
not cover the early AKT activation phase and the limited number
of studied specimens. Altered ERK signaling under hypoxia
is consistent with previously reported sustained ERK signaling
(Mitchell et al., 1999). We hypothesize that the hypoxia-induced
MIF secretionmay be linked with an altered CD74/ERK signaling
response in ASCs, which in turn may activate HIF-1α.
Migration inhibitory factors role in cell migration, cell
proliferation, wound repair and many more fundamental cell
functions is well documented (Abe et al., 2000; Zhao et al.,
2005; Dewor et al., 2007). To investigate whether an increase
of MIF upon tissue hypoxia may be a paracrine/autocrine
protective mechanism to stimulate ASC viability and to evaluate
MIF’s role as a potential agent to treat ASCs (e.g., in oxygen-
depleted wounds), recombinant MIF was added to ASCs under
hypoxia. First, we assessed the activation of ERK and AKT,
which both exert pro-survival and pro-proliferative effects
on multiple cell types. Following stimulation with increasing
concentrations of recombinant MIF, a tendency toward a dose-
dependent phosphorylation of AKT and ERK was observed.
Yet, stimulation with increasing concentrations of recombinant
MIF did not increase the viability of hypoxic ASCs when
compared to the unstimulated hypoxic control. However, this
observation is in line with our other findings that hypoxic ASCs
from chronic-non-healing wounds, which secreted significant
amounts of MIF, exhibited no increased proliferation when
compared to hypoxic ASCs from healthy adipose tissue, which
only released basal levels of MIF. It was shown earlier that
HIF-1α induces MIF expression (Welford et al., 2006; Simons
et al., 2011), while MIF amplifies HIF-1α stabilization via the
CD74/MAPK/PI3K pathway (Gaber et al., 2011), prompting a
positive feedback that leads to further MIF expression (Winner
et al., 2007). An enhanced proliferation of hypoxic ASCs has been
demonstrated to involve HIF-1α activation, FGF2 production
and activation of ERK1/2 and AKT (Kakudo et al., 2015). To
elucidate a possible link between secreted exogenous MIF, CD74,
HIF-1α expression and ASC proliferation, we assessed HIF-
1α and CD74 levels in normoxic and hypoxic ASCs treated
with recombinant MIF. In accordance to previous findings, we
demonstrated that HIF-1α is stabilized in ASCs subjected to
hypoxia (Stubbs et al., 2012; Yamamoto et al., 2013; Kakudo
et al., 2015), and that HIF-1α levels were synergistically amplified
in the presence of recombinant MIF (Fu et al., 2010; Gaber
et al., 2011). In contrast, CD74 levels remained stable following
treatment with hypoxia and recombinant MIF. Because we
observed an enhanced HIF-1α stabilization as well as a possible
AKT and ERK activation following stimulation with recombinant
MIF, our data might confirm previous results that MIF/CD74
interaction enhances HIF-1α stabilization through activation of
ERK and AKT pathway (Gaber et al., 2011). Previously, HIF-
1α activation, FGF2 production and activation of ERK1/2 and
AKT has been implicated to mediate enhanced proliferation of
human ASCs under hypoxia (Kakudo et al., 2015). Although,
we showed that recombinant MIF enhances stability of HIF-
1α and might dose-dependently phosphorylate ERK1/2 and
AKT, we did not observe an enhanced proliferation of ASCs
subjected to recombinant MIF and hypoxic tension. In summary,
based on our experiments MIF-induced HIF-1α stabilization
appears not to culminate in an increased proliferation rate of
ASCs under hypoxia.
Recently, the paracrine action of ASCs has been recognized
as the key mechanism by which ASCs exert their regenerative
potential (Salgado et al., 2010; Frese et al., 2016). In experimental
tissue engineering studies, for instance, it was shown that
implanted ASCs quickly disappeared within a few days but
attracted immune cells which promoted subsequent reparative
effects (Roh et al., 2010). Since MIF acts as an upstream regulator
ofmultiple cytokines (Calandra and Roger, 2003), we investigated
the secretion profile of IL-6, IL-1β, and TNF-α, which have been
shown to be secreted by MSCs (Paquet et al., 2015; Antebi et al.,
2018) and to be downstream of MIF (Calandra and Roger, 2003).
The profile of soluble factors released by MSCs is profoundly
influenced by sex, age, species, underlying disease conditions
and environmental factors like hypoxia or other cytokine stimuli
(Malhotra et al., 2021).
Interleukin-6 is a pleiotropic cytokine with various
inflammatory but also homeostatic effects, IL-6 released
from ASCs has been demonstrated to promote angiogenesis
and wound healing in a paracrine fashion (Heo et al., 2011; Pu
et al., 2017). Previous studies have shown that IL-6 secretion
can be triggered by several stimuli, including hypoxia (Tamm
et al., 1998) and MIF-induced CD74 activation (Xiong et al.,
2014). In our study, we detected an almost two-fold increase
of soluble IL-6 released from hypoxic ASCs when compared to
normoxic control. However, the difference was not significant
due to high sample to sample variation, which may be explained
by the heterogenous characteristics of donors, including age,
sex and different donor sites of adipose tissue. The stimulation
with recombinant MIF did not induce an increased IL-6 release
when compared to the control group. Additionally, blocking
exogenous MIF in hypoxic ASCs from chronic non-healing
adipose tissue did not diminished IL-6 levels in the supernatant.
Furthermore, comparable levels of IL-6 between ASCs from
healthy and inflamed donor sites following hypoxia confirm the
results of the MIF stimulation experiments that IL-6 secretion
remains unaffected by higher concentrations of exogenous MIF.
This indicates that IL-6 release from ASCs is mostly regulated by
hypoxia rather than by MIF.
Previous studies reported that MSCs secrete TNF-α and
IL-1β (Harrell et al., 2019) and that their paracrine action
is involved in immunomodulatory effects (Malhotra et al.,
2021). Furthermore, TNF-α and IL-1β are commonly used
to precondition of MSCs and ASCs as they profoundly
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modulate their secretome (Lee et al., 2010). In our work, TNF-
α was continuously secreted independent of applied stimuli
(hypoxia or recombinant MIF alone or in combination), while
IL-1β was significantly decreased following treatment with
recombinant MIF. However, blocking the paracrine/autocrine
activity of endogenous MIF in hypoxic ASCs from chronic
non-healing adipose tissue significantly reduced TNF-α levels in
the supernatant. Although not significant, IL-1β also showed a
tendency toward reduced secretion following neutralization of
exogenous MIF. Furthermore, similar levels of TNF-α as well as
lower levels of IL-1β released from hypoxic ASCs from inflamed
donor sites compared to hypoxic ASCs from healthy donor sites
confirm the results of the MIF stimulation experiments that IL-
1β secretion is reduced by pathophysiological externalMIF levels,
while TNF-α secretion remains unaffected by pathophysiological
external MIF. Accordingly, Meyer-Siegler et al. (2004) reported
that anti-MIF antibody treatment significantly reduced mRNA
expression and secretion of TNF-α in human bladder cancer
cells. Thus, our results demonstrate that exogenous MIF is
required for the expression and/or secretion of TNF-α in
ASCs, while supplementing supra-physiological concentrations
of recombinant MIF did not enhance TNF-α release. One may
hypothesize that exogenous MIF, regardless of its concentration,
maintains low basal amounts of exogenous TNF-α, which in
turn triggers the release of soluble factors from ASCs. Regarding
the secretion of IL-1β, a recent study from Lang et al. (2018)
has shown that intracellular MIF is involved in the assembly
and activation of the NLRP3 inflammasome which subsequently
triggers IL-1β release. However, stimulation of Mif−/− BMDMs
treated with recombinant MIF did not facilitate the NLRP3
inflammasome activation, which indicated a role for cell-
intrinsic, intracellular MIF. Furthermore, the transcription of
IL-1β is neither affected by inhibition or depletion of intracellular
MIF nor by neutralization of exogenous MIF (Meyer-Siegler
et al., 2004), In contrast to findings of Lang et al. (2018) who
reported that recombinant MIF cannot restore IL-1β levels in
Mif -deficient cells, our current findings and the results from
Meyer-Siegler et al. (2004) indicate that blocking exogenous
MIF significantly inhibits IL-1β secretion. A possible but to
our knowledge not yet proven mechanism may be a MIF-
dependent activation of protein kinase A (PKA) (Mitchell
et al., 1999; Shi et al., 2006), which in response inhibits the
inflammasome assembly by phosphorylation of human NLRP3
at Ser295 (Mortimer et al., 2016; Caseley et al., 2020). Whether
reduced IL-1β levels may be beneficial for the maintenance of
biological activity of ASCs itself or for the modulation of cellular
functions of other cell types via a paracrine action remains
to be elucidated.
Our study has limitations. First, we did not study effects
on other cellular functions such as differentiation or migration,
and other cell types such as resident cells in the subcutaneous
adipose tissue layer (e.g., macrophages, adipocytes). Second, a
major limitation of this study is the low number of patient
samples. Particularly the harvest of sufficient volumes of adipose
tissue from patients with chronic non-healing wounds and
the subsequent harvest are challenging. While considerable
amounts of adipose tissue were needed for the experiments, the
debridement of chronic wounds has to be carefully performed
and mostly includes only infected or necrotic adipose tissue of
which a great part again serves as samples for clinical diagnostics.
Thus, the majority of the collected tissue had to be discarded
due to insufficient cell numbers eventually. Additionally, despite
careful sample preparation, cell culture contamination was
observed frequently.
CONCLUSION
Taken together, MIF secretion and CD74 expression levels were
significantly up-regulated in ASCs from chronic non-healing
wounds under hypoxia. Although, exogenous MIF enhanced
HIF-1α stabilization in ASCs subjected to hypoxia, which
possibly involves the interaction of CD74 and downstream
activation of ERK and AKT, the viability of hypoxic ASCs
remained unaffected by exogenous MIF in general. A recently
growing body of evidence suggests that the ASC’s primary way
of action is exerted by the release of soluble factors rather than
differentiation and proliferation. In line with this assumption,
we propose that increased levels of MIF, such as found in ASCs
from chronic non-healing wounds, may promote tissue repair by
modulating the release of soluble factors and the reduction of IL-
1β by recombinant MIF supplementation. However, the precise
regulatory effects of MIF on the secretome of ASCs is elusive and
requires further investigation.
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Supplementary Figure 1 | Adipose-derived stem cell (ASC) characterization for
osteogenic, chondrogenic, and adipogenic differentiation. The trilinear
differentiation of isolated ASCs was measured in vitro be exposing ASCs to
osteogenic, chondrogenic and adipogenic differentiation media as reported earlier
(Yoshinoya et al., 2020). Osteogenic differentiation was determined by Alizarin red
staining (top), chondrogenic differentiation by Alcian blue staining (middle) and
adipogenic differentiation by oil red O staining (bottom).
Supplementary Figure 2 | Adipose-derived stem cell (ASC) characterization
by flow cytometry. The surface marker expression of ASCs was examined by
flow cytometry. ASCs were defined as cells with no expression of the
endothelial marker CD31 and hematopoietic marker CD45. ASCs were
positive for the stem cell markers CD34, CD73, CD90, and CD105 to
various degrees.
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